Clinical Trials
Last Updated: 7/18/2013
Lymphoma
Marginal Zone Lymphoma
Previously Treated
2010-0197 (Bendamustine, GA-101/Obinutuzumab): An Open-Label, Multicenter, Randomized, Phase III Study to Investigate The Efficacy and Safety Of Bendamustine Compared with Bendamustine + RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma.
2010-0811 (CAL-101/Idelalisib): A Phase I Study To Investigate The Safety And Clinical Activity Of CAL-101 In Combination With Chemotherapeutic Agents and Anti-CD20 mAb in Patients with Relapsed Or Refractory Indolent B-Cell Non- Hodgkin Lymphoma, Mantle Cell Lymphoma Or Chronic Lymphocytic Leukemia.
Follicular Lymphoma
Newly Diagnosed
2011-0805 (Rituximab + Lenalidomide vs. Rituximab + Chemotherapy): A Phase 3 Open-Label Randomized Study to Compare The Efficacy and Safety of Rituximab Plus Lenalidomide Versus Rituximab Plus Chemotherapy Followed by Rituximab In Subjects with Previously Untreated Follicular Lymphoma.
Previously Treated
2010-0197 (Bendamustine, GA-101/Obinutuzumab): An Open-Label, Multicenter, Randomized, Phase III Study to Investigate The Efficacy and Safety Of Bendamustine Compared with Bendamustine + RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma.
2010-0811 (CAL-101/Idelalisib): A Phase I Study To Investigate The Safety And Clinical Activity Of CAL-101 In Combination With Chemotherapeutic Agents and Anti-CD20 mAb in Patients with Relapsed Or Refractory Indolent B-Cell Non- Hodgkin Lymphoma, Mantle Cell Lymphoma Or Chronic Lymphocytic Leukemia.
2012-0750 (SGN-CD19A): Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate The Safety and Tolerability Of SGN-CD19A in Patients with Relapsed Or Refractory B-Lineage Non-Hodgkin Lymphoma (Grade 3 Follicular Lymphoma).
Small Lymphocytic Leukemia
Previously Treated
2010-0197 (Bendamustine, GA-101/Obinutuzumab): An Open-Label, Multicenter, Randomized, Phase III Study to Investigate The Efficacy and Safety Of Bendamustine Compared with Bendamustine + RO5072759 (GA101) in Patients With Rituximab- Refractory, Indolent, Non-Hodgkin's Lymphoma.
2010-0811 (CAL-101/Idelalisib): A Phase I Study To Investigate The Safety And Clinical Activity Of CAL-101 In Combination With Chemotherapeutic Agents and Anti-CD20 mAb in Patients with Relapsed Or Refractory Indolent B-Cell Non- Hodgkin Lymphoma, Mantle Cell Lymphoma Or Chronic Lymphocytic Leukemia.
2007-0408 (RO5045337): A Multi-Center, Open-Label Phase I Study of Single Agent RO5045337 Administered Orally in Patients with Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) In Blast Phase. or Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL).
Diffuse Large B-Cell Lymphoma
Newly Diagnosed
2009-0833 (Rituximab, Dose Adjusted EPOCH): Phase II Study of Dose-Adjusted Epoch+/- Rituximab In Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
2010-0822 (Imaging): FLT-PET/CT vs. FDG-PET/CT for Therapy Monitoring of Diffuse Large B-Cell Lymphoma
2009-0793 (Everolimus/RAD001): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Of RAD001 Adjuvant Therapy In Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo after Patients have Achieved Complete Response With First-Line Rituximab Chemotherapy.
Previously Treated
2011-0442 (Brentuximab Vedotin): A Phase 2 Study Of Brentuximab Vedotin (SGN-35) In Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphoma.
2011-0467 (AUY922): A Phase II Study of the HSP90 Inhibitor AUY922 In Patients with Relapsed and Refractory Lymphoma.
2011-0856 (Ruxolitinib): A Phase 2 Multicenter, investigator initiated study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma
2012-0137 (IPI-145): A Phase 1 Study of IPI-145 in Patients with Advanced Hematologic Malignancies.
2012-0750 (SGN-CD19A): Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate The Safety and Tolerability Of SGN-CD19A in Patients with Relapsed Or Refractory B-Lineage Non-Hodgkin Lymphoma. (B-NHL)
2011-0681 (AEB071): An Open-Label, Single-Arm, Phase I Study of AEB071 (A Protein Kinase C Inhibitor) in Patients with CD79-Mutant Diffuse Large B-Cell Lymphoma.
Hodgkin's Lymphoma
Newly Diagnosed
2009-0292 (Rituximab, ABVD): Phase III Study Comparing Rituximab-Supplemented ABVD (R-ABVD) With ABVD Followed by Involved-Field Radiotherapy (ABVD-RT) In LIMITED-Stage (STAGE I-IIA With No Areas of Bulk) Hodgkin's Lymphoma.
Previously Treated
2010-0065 (Panobinostat, ICE): Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study Of ICE Compared with Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma.
Mantle Cell Lymphoma
Newly Diagnosed
2013-0056 (Bendamustine, Rituximab, Ibrutinib): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma.
2006-0697 (Bortezomib, Rituximab, HyperCVAD alternating with Bortezomib, Rituximab, Methotrexate, Cytarabine): Phase I/II study of Bortezomib (VELCADE) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High-Dose Methotrexate/Cytarbine In Patients with Untreated Aggressive Mantle Cell Lymphoma.
Previously Treated
2012-0188 (Carfilzomib, Lenalidomide, Rituximab): A Phase I/II Study Of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.
2010-0811 (CAL-101/Idelalisib): A Phase I Study to Investigate the Safety And Clinical Activity of CAL-101 In Combination with Chemotherapeutic Agents and Anti-CD20 mAb in Patients with Relapsed or Refractory Indolent B-Cell Non- Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
2012-0750 (SGN-CD19A): Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate The Safety and Tolerability Of SGN-CD19A in Patients with Relapsed Or Refractory B-Lineage Non-Hodgkin Lymphoma (B-NHL).
2013-0090 (Ibrutinib + Rituximab): A Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma.
Burkitt's Lymphoma
Newly Diagnosed
2009-0833 (Rituximab, Dose Adjusted EPOCH): Phase II Study of Dose-Adjusted Epoch+/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
T-Cell Lymphoma
Newly Diagnosed
2012-0630 (Brentuximab, CHP): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-Cell lymphomas
Previously Treated
2012-0183 (Romidepsin, ICE): Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
2011-0467 (AUY922): A Phase II Study of the HSP90 Inhibitor AUY922 In Patients with Relapsed and Refractory Lymphoma.
2012-0137 (IPI-145): A Phase 1 Study of IPI-145 in Patients with Advanced Hematologic Malignancies.
2011-0183 (Carfilzomib): Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma.
2011-0856 (Ruxolitinib): A Phase 2 Multicenter, investigator initiated study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma.
Castleman's Disease
2010-0907 (Siltuximab): An Open-Label, Multicenter Study to Evaluate the Safety of Long-Term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease.
Myeloma
Smoldering Asymptomatic Lymphoma
2012-0089 (PVX-410): A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients with Smoldering Multiple Myeloma.
Newly Diagnosed
SWOGS1211 (High Risk Myeloma): Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma
2006-0022 (Minocycline): Phase II Study of Minocycline vs. Placebo to Prevent Treatment-Induced Neuropathy in Multiple Myeloma.
2010-0815 (Lenalidomide, Bortezomib, Dexamethasone): A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.
2011-0192 (Lenalidomide, Bortezomib, Dexamethasone, Panobinostat): Phase I/Ib Trial of Efficacy and Safety of the Combination Therapy of Lenalidomide, Bortezomib, Dexamethasone and Panobinostat in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma.
Previously Treated
2012-0107 (Oral LGH447): A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients with Relapsed and/or Refractory Multiple Myeloma.
2012-0573 (Carfilzomib + Dexamethasone vs. Bortezomib + Dexamethasone): A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma
2010-0295 (hLL-1-DOX): A Phase I/II Study of hLL-1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients with Multiple Myeloma.
2010-0733 (Panobinostat + Carfilzomib): Phase I/Ib Study of the efficacy and safety of the combination of Panobinostat + Carfilzomib in Patients with Relapsed/Refractory Myeloma.
2011-0144 (ARRY-520): A Phase I Study of ARRY-520 (Kinesin Inhibitor) and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
2011-0167 (ACY-1215): A Phase I/II, Open-label, Multicenter Study of ACY-1215 (Hystone Deactylase or HDAC Inhibitor) Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed-Refractory Multiple Myeloma.
2011-0336 (Carfilzomib, Dexamethasone, Pomalidomide): A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.
Myeloma Patients With Renal Impairments
2012-0205 (Pomalidomide + Dexamethasone): A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety 0f Pomalidomide When Given in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma and Impaired Renal Function.
Maintenance Therapy After Stem Cell Transplant
2012-0277 (Lenalidomide, MLN 9708): Phase II Study of the Combination of MLN 9708 with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma.
Waldenstrom's Macroglobulinemia
2009-0972 (Pomalidomide): Phase I Study of Pomalidomide in Relapsed or Refractory Waldenstrom's Macroglobulinemia.